COMMUNIQUÉS West-GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17/07/2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent [...]
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
17/07/2024
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited [...]
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
17/07/2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent [...]
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
16/07/2024
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial collaboration and [...]
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
16/07/2024
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
16/07/2024
AUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the [...]
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements
16/07/2024
Reaffirms commitment to regaining compliance with the NYSE American continued listing standards MINNEAPOLIS, MN, July 16, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), [...]
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
16/07/2024
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it [...]
Inari Medical to Announce Second Quarter 2024 Financial Results
16/07/2024
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
Surgery Partners, Inc. Announces Second Quarter 2024 Earnings Release Date and Conference Call Details
16/07/2024
BRENTWOOD, Tenn., July 16, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
16/07/2024
GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16/07/2024
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified [...]
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
16/07/2024
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc [...]
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
16/07/2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
16/07/2024
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern [...]
TeamHealth launches Post-Acute Care Medical Director Leadership Academy
16/07/2024
KNOXVILLE, Tenn., July 16, 2024 (GLOBE NEWSWIRE) -- TeamHealth is excited to announce the launch of the Post-Acute Care Medical Director Leadership Academy (MDLA), a groundbreaking program aimed at empowering medical [...]
Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI
16/07/2024
SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage following acute ST-elevation [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024
16/07/2024
Aggregated presentation by day and by market Purchases of own shares from July 8th to 12th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 28 - 2024
16/07/2024
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 8 au 12 juillet 2024 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]

Pages